US Stock MarketDetailed Quotes

ARVN Arvinas

Watchlist

9.210
+0.160+1.77%

Close Apr 28 16:00 ET

9.210
0.0000.00%

Post 20:01 ET

633.39MMarket Cap-3.32P/E (TTM)

Arvinas Stock Forum

Teddy123

13 hours ago

Arvinas Shares New Preclinical Combination Data for the PROTAC BCL6 Degrader, ARV-393, at the 2025 American Association for Cancer Research Annual

$Arvinas (ARVN.US)$
Revolutionary Cancer Drug Shows Perfect Response Rate: Arvinas' ARV-393 Eliminates Tumors in Groundbreaking Study

Teddy123

Apr 23 22:59

Arvinas Announces Results from the VERITAC-2 Trial Selected as Late-Breaking Oral Presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

$Arvinas (ARVN.US)$
First Pivotal Data for Revolutionary Breast Cancer Drug to be Unveiled at ASCO 2025 Late-Breaking Session

Teddy123

Apr 21 19:02

Arvinas to Present Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at 2025 American Association for Cancer Research® (AACR) Annual Meeting

$Arvinas (ARVN.US)$
Breakthrough Cancer Treatment ARV-393 Demonstrates Powerful Results Against Lymphoma in Latest Research

MMile Contractor

Mar 11 19:42

$Arvinas (ARVN.US)$ What happen bruh

Teddy123

Mar 11 18:48

Arvinas and Pfizer Announce Positive Topline Results from Phase 3 VERITAC-2 Clinical Trial

$Arvinas (ARVN.US)$
First-Ever PROTAC Cancer Drug Hits Major Trial Milestone: What This Means

Moomoo AI

Feb 27, 2024 03:36

Arvinas' high P/S ratio could be worrisome as revenue forecasts are not promising. The anticipated future revenues may not sustain the current positive sentiment. Without significant improvements, these prices may not be deemed reasonable.

Revenues Not Telling The Story For Arvinas, Inc. (NASDAQ:ARVN) After Shares Rise 28%

Moomoo AI

Feb 21, 2024 05:08

Sean Cassidy expressed confidence in the company's future and the promising clinical development and commercial opportunity for the PROTAC(R) protein degrader pipeline. The company's leadership acknowledged Cassidy's pivotal role in creating Arvinas' strong financial profile.

Press Release: Arvinas Announces Chief Financial Officer Transition

JP88

Dec 9, 2023 07:35

$Arvinas (ARVN.US)$ I hope everyone bought that sub 14 dip! This thing has been a beast.

Analysts Notebook

Jun 21, 2022 19:06

Columns Top upgrades and downgrades on 6/21: XOM, ADBE, UAA, BEKE and more

Upgrades
• $ABM Industries (ABM.US)$ : Baird Upgrades to Outperform from Neutral - PT $50
• $American Tower Corp (AMT.US)$ : JPMorgan Upgrades to Overweight from Underweight - PT $285 (from $245)
• $Church & Dwight (CHD.US)$ : Wells Fargo Upgrades to Overweight from Equal Weight - PT $95
• $Chewy (CHWY.US)$ : Wedbush Upgrades to Outperform from Neutral - PT $35 (from $30)
• $Centene (CNC.US)$ : Credit Suisse Upgrades to Outperform from...

Analysts Notebook

May 9, 2022 18:50

Columns Top upgrades and downgrades on 5/9

Upgrades
• $Cigna Group (CI.US)$ : Cowen Upgrades to Outperform from Market Perform - PT $329 (from $242)
• $DLocal (DLO.US)$ : New Street Research Upgrades to Buy from Neutral - PT $38
• $Goodyear Tire & Rubber (GT.US)$ : CFRA Upgrades to Buy from Hold - PT $20 (from $24)
• $Match group (MTCH.US)$ : Wells Fargo Upgrades to Overweight from Equal Weight - PT $115 (from $140)
• $Prestige Consumer Healthcare (PBH.US)$ : Oppenheimer Upgrades to Outperform from Perform - P...